RACE:NYSEFerrari N.V. Analysis
Data as of 2026-03-16 - not real-time
$331.05
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Ferrari (RACE) trades around $331, just above its 20‑day SMA ($358) but well below the 200‑day SMA ($422), signaling a long‑term downtrend despite a neutral short‑term direction. The RSI of 34 suggests the stock is approaching oversold territory, while a bearish MACD histogram reinforces momentum weakness. Volatility is elevated at 40% over the past 30 days, yet the beta of 0.65 points to lower systematic risk relative to the market. Fundamentally, the company boasts a 51.7% gross margin, a 28.6% operating margin, and a solid ROE of 42.9%, supported by a healthy cash position and a modest payout ratio of 33%.
However, the DCF fair value of roughly $68 is dramatically lower than the current price, implying the stock is significantly overvalued. Strong order books and a strategic buy‑back program provide upside catalysts, but the valuation gap and high short‑term volatility suggest caution.
However, the DCF fair value of roughly $68 is dramatically lower than the current price, implying the stock is significantly overvalued. Strong order books and a strategic buy‑back program provide upside catalysts, but the valuation gap and high short‑term volatility suggest caution.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering near recent support at $329.33
- Bearish MACD and low RSI indicating potential short‑term bounce risk
- Decreasing volume trend limiting immediate upside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong profitability metrics (gross margin >50%, operating margin >28%)
- Robust cash flow and low payout ratio supporting dividend sustainability
- Positive analyst sentiment (median target $429) and strategic buy‑back program
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Premium brand positioning and limited production capacity ensuring pricing power
- Exposure to consumer‑cyclical demand and macro‑economic cycles
- Significant valuation premium relative to DCF fair value requiring re‑rating
Key Metrics & Analysis
Financial Health
Revenue Growth3.80%
Profit Margin22.35%
P/E Ratio32.0
ROE42.89%
ROA13.75%
Debt/Equity73.68
P/B Ratio13.1
Op. Cash Flow$2.3B
Free Cash Flow$839.1M
Technical Analysis
TrendNeutral
RSI34.0
Support$329.33
Resistance$381.76
MA 20$358.25
MA 50$355.14
MA 200$422.43
MACDBearish
VolumeDecreasing
Fear & Greed Index78.27
Valuation
Fair Value$67.63
Target Price$440.38
Upside/Downside33.03%
GradeOvervalued
TypeGrowth
Dividend Yield1.29%
Risk Assessment
Beta0.65
Volatility40.36%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.